Ning Lyu

651 Dongfeng East Road
Guangzhou, 510060, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 44 publications

Transarterial Chemoembolization Plus Thermal Ablation in Unresectable Hepatocellular Carcinoma: The Phase 3 TORCH Randomized Clinical Trial.

Transarterial Chemoembolization Plus Thermal Ablation in Unresectable Hepatocellular Carcinoma: The Phase 3 TORCH Randomized Clinical Trial.

Journal: JAMA oncology

Published: July 30, 2026

Concomitant medication use and clinical outcome in hepatocellular carcinoma treated with immune-based therapy: a multicenter analysis.

Concomitant medication use and clinical outcome in hepatocellular carcinoma treated with immune-based therapy: a multicenter analysis.

Journal: Frontiers in immunology

Published: August 13, 2025

Interventional arterial chemotherapy versus sorafenib for advanced hepatocellular carcinoma in China: a health economic evaluation of open-label, randomised, phase 3 study.

Interventional arterial chemotherapy versus sorafenib for advanced hepatocellular carcinoma in China: a health economic evaluation of open-label, randomised, phase 3 study.

Journal: BMJ open

Published: May 28, 2025

Matching-Adjusted Indirect Comparison of Arterial FOLFOX and Atezolizumab-Bevacizumab in Unresectable Hepatocellular Carcinoma.

Matching-Adjusted Indirect Comparison of Arterial FOLFOX and Atezolizumab-Bevacizumab in Unresectable Hepatocellular Carcinoma.

Journal: Liver cancer

Published: January 22, 2025

A Metrology Informatics Investigation of Conversion Therapy in Hepatocellular Carcinoma: 2014-2023.

A Metrology Informatics Investigation of Conversion Therapy in Hepatocellular Carcinoma: 2014-2023.

Journal: Annals of surgery open : perspectives of surgical history, education, and clinical approaches

Published: October 23, 2024

Efficacy and safety of arterial FOLFOX chemotherapy plus anti-PD-(L)1 immunotherapy as a first-line treatment for unresectable intrahepatic cholangiocarcinoma: a propensity score matching analysis.

Efficacy and safety of arterial FOLFOX chemotherapy plus anti-PD-(L)1 immunotherapy as a first-line treatment for unresectable intrahepatic cholangiocarcinoma: a propensity score matching analysis.

Journal: Journal of gastrointestinal oncology

Published: July 19, 2024

Hepatic arterial infusion therapy for advanced hepatocellular carcinoma after systemic treatment failure: A treatment dilemma-Authors' reply.

Hepatic arterial infusion therapy for advanced hepatocellular carcinoma after systemic treatment failure: A treatment dilemma-Authors' reply.

Journal: Hepatology research : the official journal of the Japan Society of Hepatology

Published: June 29, 2024

Additional Hepatic Arterial Infusion Chemotherapy to Sorafenib Was Cost-Effective for Hepatocellular Carcinoma with Major Portal Vein Tumor Thrombosis.

Additional Hepatic Arterial Infusion Chemotherapy to Sorafenib Was Cost-Effective for Hepatocellular Carcinoma with Major Portal Vein Tumor Thrombosis.

Journal: Journal of hepatocellular carcinoma

Published: April 20, 2024

Recommended 10-Year Follow-Up Strategy for Small Hepatocellular Carcinoma After Radiofrequency Ablation: A Cost-Effectiveness Evaluation.

Recommended 10-Year Follow-Up Strategy for Small Hepatocellular Carcinoma After Radiofrequency Ablation: A Cost-Effectiveness Evaluation.

Journal: The American journal of gastroenterology

Published: November 20, 2023

CircMYBL2 facilitates hepatocellular carcinoma progression by regulating E2F1 expression.

CircMYBL2 facilitates hepatocellular carcinoma progression by regulating E2F1 expression.

Journal: Oncology research

Published: November 08, 2023

Hepatic arterial infusion therapy for advanced hepatocellular carcinoma after systemic treatment failure: Multicenter, real-world study.

Hepatic arterial infusion therapy for advanced hepatocellular carcinoma after systemic treatment failure: Multicenter, real-world study.

Journal: Hepatology research : the official journal of the Japan Society of Hepatology

Published: October 17, 2023

Improving the Conversion Success Rate of Hepatocellular Carcinoma: Focus on the Use of Combination Therapy with a High Objective Response Rate.

Improving the Conversion Success Rate of Hepatocellular Carcinoma: Focus on the Use of Combination Therapy with a High Objective Response Rate.

Journal: Journal of clinical and translational hepatology

Published: September 05, 2023

Showing 1-12 of 44

Last Updated: 09/26/2026